Distinct requirements for Ras oncogenesis in human versus mouse cells by Hamad, N. M.
Distinct requirements for Ras
oncogenesis in human versus mouse cells
Nesrin M. Hamad,1,4 Joel H. Elconin,1,4,5 Antoine E. Karnoub,3 Wenli Bai,1 Jeremy N. Rich,2
Robert T. Abraham,1,6 Channing J. Der,3 and Christopher M. Counter1,7
1Departments of Pharmacology and Cancer Biology and Radiation Oncology and 2Department of Medicine, Division of
Neurology, Duke University Medical Center, Durham North Carolina 27710, USA; 3Department of Pharmacology,
Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina 27599, USA
The spectrum of tumors associated with oncogenic Ras in humans often differs from those in mice either
treated with carcinogens or engineered to sporadically express oncogenic Ras, suggesting that the mechanism
of Ras transformation may be different in humans. Ras stimulates primarily three main classes of effector
proteins, Rafs, PI3-kinase, and RalGEFs, with Raf generally being the most potent at transforming murine
cells. Using oncogenic Ras mutants that activate single effectors as well as constitutively active effectors, we
find that the RalGEF, and not the Raf or PI3-kinase pathway, is sufficient for Ras transformation in human
cells. Thus, oncogenic Ras may transform murine and human cells by distinct mechanisms, and the RalGEF
pathway—previously deemed to play a secondary role in Ras transformation—could represent a new target for
anti-cancer therapy.
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Extracellular signals detected by cell-surface receptors
can be transmitted to the cell by stimulating the conver-
sion of the Ras oncoprotein from an inactive GDP-bound
to an active GTP-bound state. In the GTP-bound state,
Ras stimulates downstream targets, or effectors, which,
in turn, affect numerous activities of the cell, such as
proliferation, apoptosis, and differentiation (Shields et al.
2000). Mutated and constitutively activated forms of Ras
are found in 30% of all human cancers (Bos 1989). Sig-
nificant experimental and epidemiological evidence sup-
ports that such aberrant Ras activation plays a critical
role in human oncogenesis. Consequently, there is con-
siderable effort to develop inhibitors of the Ras-signaling
pathway for use as novel anticancer drugs (Kloog and
Cox 2000; Shields et al. 2000).
Ras transformation is mediated by interactions with
multiple downstream effectors whose contribution to
Ras transformation has been evaluated primarily in ro-
dent fibroblast model cell systems. Substantial evidence
from these studies supports the role of Raf serine/threo-
nine kinases (c-Raf-1, A-Raf, and B-Raf) as key effectors
and mediators of Ras-transforming activity. Raf kinases
phosphorylate and activate the MEK1 and MEK2 dual
specificity kinases, which, in turn, phosphorylate and
activate the ERK1/p44 and ERK2/p42 mitogen-activated
protein kinases (MAPKs) (Kyriakis et al. 1992). The criti-
cal contribution of the Raf/MEK/ERK pathway to Ras
transformation is shown by the ability of constitutively
activated mutants of Raf or MEK to cause tumorigenic
transformation of NIH 3T3 cells (Bonner et al. 1985;
Stanton et al. 1989; Leevers et al. 1994; Stokoe et al.
1994). Additionally, dominant-negative mutants of Raf-
1, MEK, and ERK, as well as pharmacologic inhibitors of
MEK, have been shown to effectively block Ras transfor-
mation in vitro or suppress tumorigenic growth of cancer
cell lines in vivo (Kolch et al. 1991; Schaap et al. 1993;
Cowley et al. 1994; Westwick et al. 1994; Khosravi-Far et
al. 1995; Qiu et al. 1995; Monia et al. 1996; Sebolt-Leo-
pold et al. 1999).
Perhaps the second best-characterized effector impor-
tant for Ras transformation is phosphatidylinositol 3-ki-
nase (PI3-kinase). Activated PI3-kinase, a lipid kinase,
facilitates the conversion of phosphatidylinositol 4,5-
bisphosphate (PIP2) to phosphatidylinositol 3,4,5-tris-
phosphate (PIP3). PIP3 levels are elevated in Ras-trans-
formed cells. Dominant-negative mutants of PI3-kinase
can effectively block Ras transformation of NIH 3T3
cells. Finally, whereas activated PI3-kinase alone cannot
cause transformation of NIH 3T3 cells, activated vari-
ants of PI3-kinase can cooperate with activated Raf to
cause synergistic transforming activity (Rodriguez-Vici-
ana et al. 1997).
The third class of effectors with a role in Ras transfor-
mation are guanine nucleotide exchange factors (GEFs)
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for the Ral small GTPases, RalGDS, RGL, RGL2/Rlf,
and RGL3 (Wolthuis and Bos 1999). Inhibition of these
RalGEFs by expression of a dominant-negative Ral pro-
tein blocks Ras focus formation or hematogenous meta-
static growth of specific cell lines (Urano et al. 1996;
White et al. 1996; Lu et al. 2000; Ward et al. 2001). Fur-
thermore, whereas constitutively activated variants of
RalGEFs are not transforming in NIH 3T3 cells, their
coexpression with activated Raf induced synergistic fo-
cus formation (Urano et al. 1996; White et al. 1996).
Thus, although current evidence does not implicate
RalGEFs as key players in Ras transformation, they may
contribute to the process.
Activating mutations of Ras are found in humans in
nearly all pancreatic cancers, one-half of colon and thy-
roid tumors, and one-third of lung tumors (Bos 1989).
However, transgenic mice that model these sporadic Ras
mutations do not give rise to the same tumors linked to
Ras mutations of human cancer patients. In particular,
these mice fail to form pancreatic, thyroid, or colon tu-
mors (Johnson et al. 2001). Additionally, a divergent as-
sociation of Ras mutations with distinct neoplasms is
also seen when compared in humans and rodents. For
example, whereas Ras mutations are strongly associated
with the carcinogen-induced mammary carcinomas in
mice and rats (Zarbl et al. 1985; Miyamoto et al. 1990),
such mutations are rare in human breast cancers (Bos
1989). One interpretation of these results is that Ras-
mediated tumorigenic growth may display subtle, but
important differences between mice and humans. We
therefore wished to determine whether the mechanisms
of Ras-induced transformation and tumorigenesis oper-
ate in a similar fashion in mice and humans.
One drawback of studying Ras-induced transformation
in human cells is that ectopic expression of Ras causes
cellular senescence in primary human cells (Serrano et
al. 1997). However, we recently described that normal
primary human cells can be converted to a tumorigenic
state by the enforced expression of oncogenic (12V) H-
Ras and two other genes, hTERT and the early region of
SV40. hTERT is the catalytic subunit of telomerase (Na-
kamura and Cech 1998), which is essential to immortal-
ize human cells (Bodnar et al. 1998; Counter et al. 1998;
Vaziri and Benchimol 1998) and is illegitimately acti-
vated to restore telomerase activity in 85% of human
cancers (Shay and Bacchetti 1997). The SV40 early region
encodes the oncoproteins T and t-Ag, which transform
mammalian cells through, in part, disrupting the func-
tions of the tumor suppressor proteins p53 and Rb (Liv-
ingston 1992; Ludlow 1993) and the phosphatase PP2A
(Sleigh et al. 1978; Rubin et al. 1982; Pallas et al. 1990;
Hahn et al. 2002). SV40 DNA, virus, or the T-Ag onco-
protein have also been detected specifically in tumor,
but not adjacent tissues, from a wide spectrum of can-
cers, potentially implicating this virus in the etiology of
certain human tumors (Bergsagel et al. 1992; Carbone et
al. 1994; Lednicky et al. 1995; Martini et al. 1996). Ex-
pression of the T-Ag gene, hTERT, and H-Ras12V in pri-
mary cultures of human fibroblasts, embryonic kidney,
mammary epithelial, and astrocyte cells leads to the cre-
ation of sarcomas (Hahn et al. 1999), carcinomas (Hahn
et al. 1999; Elenbaas et al. 2001), and glioblastomas (Rich
et al. 2001), respectively, suggesting that ectopic expres-
sion of these genes comprise a core set of changes re-
quired for tumor growth of human cells. Moreover, be-
cause oncogenic Ras is absolutely required for these cells
to become tumorigenic, primary cultures of human cells
expressing large and small T-Ag and hTERT proteins
provide a genetically defined system to circumvent the
above limitation, allowing for the study of Ras-mediated
oncogenesis in human cells. Although this system does
not mimic the gradual selection of spontaneous muta-
tions over time, it does allow one to delineate the con-
tribution of specific genetic changes to the tumorigenic
process, starting with primary human cells. Therefore, in
this study, we utilized these human cell model systems
to evaluate the role of specific effectors in mediating Ras
transformation. Our results reveal a striking difference
in the contribution of distinct effector pathways to Ras
transformation in rodent and human cells, and suggest
that RalGEF may play a key role in Ras-mediated human
oncogenesis.
Results
Ras12V37G, but not Ras12V35S, transforms
human cells
As a first step to elucidate the signaling pathways
through which Ras transforms human cells, we sought
to determine which effectors of Ras are essential for the
transformation of primary human cells. Activated Ras
binds its downstream effectors through the core effector
domain (residues 32–40). Specific missense mutations in
this domain of H-Ras12V that selectively impair the
binding and activation of Raf, PI3-kinase, and RalGEFs
have been utilized widely to delineate the role of the
specific effector pathways in Ras function. Oncogenic
H-Ras12V with the mutations T35S, Y40C, or E37G bind
to and activate primarily Raf, PI3-kinase, or RalGEFs,
respectively. In NIH 3T3 cells, the H-Ras12V35S mutant
shows much greater potency than either the 37G or 40C
mutants, providing important evidence that Ras trans-
formation of rodent fibroblasts is mediated primarily
through Raf (White et al. 1995; Khosravi-Far et al. 1996;
Shields et al. 2000). Therefore, we utilized H-Ras12V ef-
fector domain mutants to evaluate the importance of
Raf, PI3-kinase, and RalGEFs to Ras transformation of
human cells.
Prior to evaluating the Ras effector domain mutants in
human cells, we verified that our expression vectors for
each effector mutant exhibited the differential ability to
transform NIH 3T3 cells, as has been described in previ-
ous studies (White et al. 1995; Khosravi-Far et al. 1996;
Shields et al. 2000). The three described effector domain
mutants of H-Ras12V, oncogenic H-Ras12V as a positive
control, the null vector, or nontransforming H-Ras as
dual negative controls were stably introduced into NIH
3T3 mouse fibroblasts. Immunoblot analysis for ectopic
Ras in extracts isolated from the resultant polyclonal
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populations revealed a similar amount of this protein in
each of the Ras-infected cells (Fig. 1A), presumably at
levels higher than typically observed in cancer cells.
Cells were next assayed for growth in soft agar. This
assay is one of the most rigorous tests of cellular trans-
formation in vitro and provides the best in vitro correlate
to tumorigenic growth potential. Additionally, poly-
clonal populations were assayed immediately after infec-
tion to limit the possibility of cells with sporadic muta-
tions skewing the transformation properties of the cul-
ture. As expected, NIH 3T3 cells failed to grow in soft
agar unless oncogenic, but not wild-type, Ras was ex-
pressed. Moreover, as reported by others, Ras12V35S,
which activates Raf but not PI3-kinase or RalGEFs
(White et al. 1995; Khosravi-Far et al. 1996; Rodriguez-
Viciana et al. 1996), was the most highly transforming
mutant when expressed in these cells (Fig. 1B).
Having shown that the Ras effector domain mutants
function as expected on the basis of the most stringent
criteria – biological transformation – we next introduced
by retroviral infection the expression vectors encoding
the same effector domain mutants and appropriate posi-
tive and negative control vectors into human cells. We
chose to first test primary human embryonic kidney
(HEK) epithelial cells that ectopically express hTERT
and the T-Ag gene (encoding large and small T-Ag).
These HEK–HT cells are ideal for assaying Ras-induced
oncogenesis, because the addition of oncogenic Ras ren-
ders them transformed, as assessed by growth in semi-
solid medium, and tumor formation when injected into
immunocompromised mice (Hahn et al. 1999). After in-
fection, the cells were assayed for H-Ras12V expression
by immunoblot analysis and for transformation by the
soft agar assay. We found that ectopic Ras was expressed
at similar levels in each of the Ras-infected cells (Fig.
1A). Surprisingly, the transformation profile of human
cells by use of the identical effector domain mutants was
quite different from that observed in NIH 3T3 cells.
Ras12V35S, which activates Raf but not PI3-kinase or
RalGEFs, did not support anchorage-independent growth
of the human HEK–HT cells (Fig. 1B), despite the fact
that this protein is the most potent effector mutant of
Ras12V in the murine NIH 3T3 cell-transformation as-
say. Rather, Ras12V37G, which activates RalGEFs but
not Raf or PI3-kinase (White et al. 1996; Rodriguez-Vici-
ana et al. 1997; Wolthuis and Bos 1999), was the only
effector domain mutant that yielded transformed growth
with human cells (Fig. 1B). These results indicate that
oncogenic Ras utilizes different signaling pathways in
the transformation of murine NIH 3T3 versus human
HEK–HT cells.
Species variation underlies the differences
in Ras-induced transformation between murine
and human fibroblasts
We envisioned three differences between NIH 3T3 and
HEK–HT cells that could account for the dramatic dis-
crepancies in Ras-induced transformation between these
cells. First, the difference may stem from the fact that
these cells are of different lineage (mesoderm vs. ecto-
derm). Second, the expression of the T-Ag gene in HEK–
HT cells, but not NIH 3T3 cells, may be a factor, espe-
cially in light of the fact that the alternatively spliced
product small t-Ag can indirectly affect MAP-kinase
function (Rubin et al. 1982). Although the HEK–HT cells
were also infected with an hTERT-encoding retrovirus to
restore telomerase activity, this gene was not considered
Figure 1. Ras12V37G transforms human cells. (A) Expression of Ras mutants was confirmed in NIH 3T3 or HEK-HT cells stably
infected with retroviruses encoding the described FLAG-tagged H-Ras cDNAs or with a vector or H-Ras control, by immunoblotting
with an anti-FLAG antibody. Actin levels serve as a loading control. (B) Anchorage-independent growth of NIH 3T3 (black bars) or
human HEK–HT (white bars) cells expressing the described constructs, calculated from the average number of colonies observed from
three plates and expressed as the percent of colonies observed in Ras12V-transformed cells. A total of 50,000 Ras12V-transformed NIH
3T3 or HEK–HT cells yielded 380 ± 50 or 289 ± 47 colonies in soft agar, respectively.
Ras oncogenesis in human cells
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a confounding factor, as NIH 3T3 cells retain expression
of the endogenous gene and are telomerase positive
(Greenberg et al. 1998). Third, species differences may be
important, because NIH 3T3 cells are murine, whereas
HEK–HT cells are human.
To directly test whether species variation underlies
the difference in transformation, we created identically
matched pairs of transformed human and murine cells
from the same cell type. Specifically, we isolated normal
primary fibroblasts from mice and humans and stably
introduced the exact same T-Ag gene into both. Equiva-
lent T-Ag expression was confirmed in both the human
and murine fibroblasts by immunoblotting with an anti-
T-Ag antibody (Fig. 2A). Additionally, because cultured
murine fibroblasts are telomerase positive (Chadeneau et
al. 1995; Greenberg et al. 1998), hTERT was stably in-
troduced into the human cells to restore telomerase ac-
tivity (data not shown; Hahn et al. 1999). The cells were
next infected with a vector control retrovirus or one en-
coding oncogenic H-Ras, or the three effector domain
mutants. Immunoblot analysis for ectopic H-Ras expres-
sion verified that the different H-Ras12V proteins were
expressed at similar levels (Fig. 2B). As before, the poly-
clonal populations were immediately assayed for anchor-
age-independent growth. We found that T-Ag expressing
primary murine fibroblasts behaved as NIH 3T3 cells, in
which Ras12V35S was still the most potent effector do-
main mutant at promoting transformation (Fig. 2C). We
also repeated the experiment with fibroblasts isolated
from a different mouse. Specifically, primary cultures of
murine fibroblasts were stably infected with retroviruses
encoding T-Ag, and Ras12V or the aforementioned effec-
tor domain mutants and assayed for anchorage-indepen-
dent growth. Although the differences between the vari-
ous effects of the mutants on anchorage-independent
growth was less pronounced, Ras12V35S was the most
potent effector domain mutant in this transformation
assay (Fig. 2D). On the other hand, the human fibroblasts
expressing T-Ag and hTERT resembled HEK–HT cells,
in which Ras12V37G was again the only effector domain
mutant capable of supporting growth in soft agar (Fig.
2C). Thus, the transforming potential of Ras12V37G in
human cells cannot be ascribed to either cell type or
expression of large or small T-antigens. The simplest in-
terpretation of these data is that the observed discor-
dance in Ras transformation is due to a fundamental dif-
ference between mouse and human cells.
Transformation profiles of Ras effector mutants are
not cell-type specific in human cells
The transformation potential of Ras effectors has been
reported to vary depending on cell type in rodents. For
example, an activated version of Raf1 promotes tumori-
genic growth of NIH 3T3 fibroblasts (Cowley et al. 1994;
Mansour et al. 1994), whereas RIE-1 epithelial cells are
Figure 2. Ras-induced transformation is different in human vs. murine cells. (A) Expression of T-Ag was confirmed in human and
murine fibroblasts stably infected with a retrovirus encoding the T-Ag gene by immunoblotting with an anti-T-Ag antibody. Actin
serves as a loading control. (B) Expression of Ras mutants was confirmed in T-Ag expressing murine and human fibroblasts (the latter
of which also ectopically express hTERT) stably infected with retroviruses encoding the described FLAG-tagged H-Ras cDNAs or with
a vector control, by immunoblotting with an anti-FLAG antibody. Actin levels serve as a loading control. (C) Anchorage-independent
growth of the aforementioned T-Ag-expressing human (black bars) and murine (white bars) fibroblasts, calculated from the average
number of colonies observed from three plates and expressed as the percent of colonies observed in Ras12V-transformed cells. A total
of 50,000 Ras12V-transformed human or mouse fibroblasts yielded 320 ± 100 or 481 ± 135 colonies in soft agar, respectively. (D)
Anchorage-independent growth of a different independently derived mouse fibroblast cell strain stably infected with constructs
encoding T-Ag and the described H-Ras mutants, calculated from the average number of colonies observed from three plates and
expressed as the percent of colonies observed in Ras12V-transformed cells. A total of 50,000 Ras12V-transformed mouse fibroblasts
yielded 497 ± 64 colonies in soft agar.
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resistant to transformation by this protein (Oldham et al.
1996). Thus, it is possible that the observed transforma-
tion of human cells by only the Ras effector mutant that
activates RalGEFs may be restricted to specific cell
types. However, we showed that both human fibroblasts
and HEK cells expressing T-Ag and hTERT behaved
identically with respect to Ras transformation. Both cell
types grew in soft agar only in the presence of the 37G
effector domain mutant of H-Ras12V (Figs. 1B and 2C).
Moreover, we found identical results with a third, com-
pletely different cell type. Human astrocytes expressing
hTERT and the T-Ag gene (Rich et al. 2001) were stably
infected with a control retrovirus or one encoding
H-Ras12V or the effector domain mutants (Fig. 3A) and
assayed for growth in soft agar. Again, the 37G effector
domain mutant was the only variant of Ras12V that re-
tained the ability to transform astrocytes (Fig. 3B). Given
that HEK cells are derived from ectoderm, fibroblast
from mesoderm, and astrocytes from neuroectoderm, we
suggest that the 37G mutant of H-Ras12V in the pres-
ence of the T-Ag gene and hTERT may promote the
growth transformation of a diverse variety of human cell
types. The signaling pathway emanating from
Ras12V37G may therefore be a general requirement for
Ras transformation of human cells.
Activation of neither the MAP-kinase nor the
PI3-kinase pathway is sufficient to transform
human cells
The observation that expression of Ras12V35S failed to
transform a wide spectrum of human cells argues that,
unlike murine fibroblasts, activation of Raf and subse-
quently the MAP-kinase pathway is alone insufficient to
transform human cells. To directly evaluate this possi-
bility, an amino-terminally truncated and constitutively
active version of Raf1, Raf1-22W (Stanton et al. 1989),
was stably expressed in HEK–HT cells (Fig. 4A). We de-
termined that HEK–HT cells stably overexpressing
Raf1-22W possessed elevated levels of phosphorylated
and activated ERK that were comparable with the el-
evated level seen in Ras-transformed HEK–HT cells. In
contrast, there was no increase in Akt phosphorylation,
a downstream target of activated PI3-kinase, indicating
the specific activation of the ERK pathway by Raf1-
22W (Fig. 4B). Having shown that Raf1-22W caused sus-
tained up-regulation of ERK in HEK–HT cells, we next
assayed the ability of these cells to grow in soft agar. In
accordance with our observations with Ras12V35S, the
resultant cells failed to form colonies in semi-solid me-
dium (Fig. 4C).
We similarly confirmed that activation of the PI3-ki-
nase pathway is not transforming. Specifically, HEK–HT
cells were infected with a retrovirus encoding p110-
CAAX, a membrane-targeted and constitutively acti-
vated version of the p110  catalytic subunit of PI3-ki-
nase (Rodriguez-Viciana et al. 1997). We verified that the
HEK–HT cells stably expressed p110-CAAX and showed
up-regulated levels of activated Akt, but not ERK (Fig.
4A,B). Similar to our results with Ras12V40C, activation
of the PI3-kinase pathway by p110-CAAX also failed to
promote growth of the HEK–HT cells in soft agar (Fig.
4C). Thus, by two different criteria, we show that selec-
tive activation of either the Raf or PI3-kinase limbs of
the Ras-signaling machinery does not promote the trans-
formed phenotype of anchorage-independent growth in
human epithelial cells.
Raf and PI3-kinase pathways fail to cooperate
to transform human cells
Although we determined that activation of Raf or PI3-
kinase alone was not sufficient to promote the transfor-
mation of HEK–HT cells, perhaps the coordinate activa-
tion of both effector pathways is required to cause
growth transformation. Evidence for this possibility is
provided by the observation that PI3-kinase, activated by
H-Ras12V40C, can cooperate with Raf activated by
H-Ras12V35S to cause synergistic transformation of
NIH 3T3 cells (Khosravi-Far et al. 1996; Rodriguez-Vici-
Figure 3. Ras12V37G transforms human astrocytes. (A) Ex-
pression of Ras mutants was confirmed in hTERT, T-Ag-ex-
pressing human astrocytes stably infected with retroviruses en-
coding the described FLAG-tagged H-Ras cDNAs or with a vec-
tor control, by immunoblotting with an anti-FLAG antibody.
Actin levels serve as a loading control. (B) Anchorage-indepen-
dent growth of the aforementioned hTERT, T-Ag human astro-
cytes expressing the described constructs, calculated from the
average number of colonies observed from three plates and ex-
pressed as the percent of colonies observed in Ras12V-trans-
formed cells. A total of 50,000 Ras12V-transformed human as-
trocytes yielded 120 ± 40 colonies in soft agar.
Ras oncogenesis in human cells
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ana et al. 1997). Therefore, we sought to determine
whether the concomitant activation by effector mutants
of both these effector pathways could, as has been ob-
served in murine cells, transform human cells.
To test whether the combination of effector domain
mutants Ras12V35S and Ras12V40C, which respectively
stimulate Raf-1 and PI3-kinase, can promote transforma-
tion, we first confirmed that introduction of a second
(null) vector had no effect on the transforming potential
of any of the effector domain mutants in HEK–HT cells
(Fig. 5A,B). Subsequently, HEK–HT cells stably express-
ing H-Ras12V35S (Fig. 1A) were stably infected with a
retrovirus encoding H-Ras12V40C. Because these effec-
tor mutants differ by only a single nucleotide, equivalent
expression of both transgenes was verified by direct se-
quencing of cDNA derived from these cells (Fig. 5A). We
then evaluated the cells for growth transformation using
the soft agar assay. We found that the combined expres-
sion of Ras12V35S and Ras12V40C could only lead to an
extremely low amount of anchorage-independent growth
when compared with the Ras-transformed control cells
(Fig. 5B). Thus, these effector domain mutants failed to
cooperate and support the transformation of human
cells. Moreover, HEK–HT cells stably infected with ret-
roviruses encoding Raf1-22W and p110-CAAX com-
pletely failed to grow in semi-solid medium (Fig. 5C).
Thus, we conclude that stimulation of both the MAP-
kinase and PI3-kinase arms of oncogenic Ras together by
two different approaches is insufficient to promote the
transformed cell growth of HEK–HT cells.
Raf and PI3-kinase enhance
Ras12V37G-induced transformation
We found it surprising that the combined activation of
both the PI3-kinase and the MAP-kinase pathways failed
to transform the human cells, especially because the
combination of these two pathways in murine cells is
known to increase transformation above that observed
with activation of either effector alone (Khosravi-Far et
al. 1996; Rodriguez-Viciana et al. 1997). However, as
Ras12V37G alone can transform human cells, albeit to a
lesser extent than oncogenic Ras, we next determined
whether the coactivation of Raf and PI3-kinase could
cooperate with 37G and cause enhanced transforming
activity. To directly test this hypothesis, we utilized Ras
effector domain mutants or activated effector proteins to
cause activation of PI3-kinase or Raf in cells coexpress-
ing H-Ras12V37G.
The expression vector encoding H-Ras12V37G was
stably introduced (Fig. 5A; data not shown) into HEK–
HT cells that had already been confirmed to express
H-Ras12V35S (Fig. 1A) or Raf1-22W (Fig. 4A). The re-
sultant cells from both experiments were then assayed
for anchorage-independent growth; we found that both
now showed colony forming efficiencies that exceeded
that seen with cells transformed by oncogenic H-Ras12V
(Fig. 5B). Thus, activation of the MAP-kinase pathway by
two independent approaches significantly enhanced the
transforming potency of Ras12V37G in human cells.
Similarly, the expression vector encoding
H-Ras12V37G was stably introduced (Fig. 5A; data not
shown) into HEK–HT cells that expressed either
H-Ras12V40C (Fig. 1A) or p110-CAAX (Fig. 4A), and the
resultant cells were assayed for growth in semi-solid me-
dium. Again, both methods to activate the PI3-kinase
pathway potentiated the transformed growth of
Ras12V37G expressing HEK–HT cells to levels greater
than that observed in Ras12V-transformed control cells
(Fig. 5B). Thus, consistent with the known roles of the
MAP-kinase and PI3-kinase pathways in human cancer,
Figure 4. Specific activation of Raf or PI3-kinase is not suffi-
cient to promote anchorage-independent growth of human
cells. (A) Expression of Raf1-22W or p110-CAAX was con-
firmed in the described HEK–HT cells by immunoblotting with
an anti-Raf1 antibody or by RT–PCR with primers specific for
p110. Actin and GAPDH levels serve as loading controls. These
cells also were infected with an empty vector. (B) Specific acti-
vation of either the MAP-kinase or PI3-kinase pathway by
Raf1-22W or p110-CAAX, respectively, was confirmed in the
described HEK–HT by immunoblotting with antibodies specific
for the phosphorylated forms of ERK1 and ERK2 or Akt. Total
ERK 1/2 and Akt levels serve as a loading control. (C) Anchor-
age-independent growth of HEK–HT cells expressing Raf1-
22W or p110-CAAX, as calculated from the average number of
colonies observed from three plates, and expressed as the per-
cent of colonies observed in Ras12V-transformed cells. A total
of 50,000 HEK–HT cells expressing H-Ras12V seeded in soft
agar yielded 311 ± 46 colonies.
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activation of these pathways does enhance transforma-
tion in human cells. However, because anchorage-inde-
pendent growth was not observed unless Ras12V37G
was expressed, these results suggest that the effector-
signaling activity of 37G plays an essential role in Ras-
induced transformation.
The Ras12V37G effectors RalGEFs transform
human cells
Because Ras12V37G is critical for the Ras oncogenesis in
human cells, we sought to identify the underlying sig-
naling pathway responsible for transformation by this
effector mutant. Although the transforming activity of
Ras12V37G is generally ascribed to its ability to activate
RalGEFs (Wolthuis and Bos 1999), this effector domain
mutant does retain the ability to interact with other pro-
teins (Khosravi-Far et al. 1996; Han et al. 1997; Lin-
nemann et al. 1999; Cullen 2001). To test whether
Ras12V37G transformation of HEK–HT cells involves
the activation of RalGEF function, we first determined
whether inhibition of RalGEF activity could impair Ras-
transforming activity. The S28N dominant-negative
mutant of RalA forms a nonproductive complex with
RalGEFs (Urano et al. 1996), impeding RalGEF activa-
tion of endogenous Ral small GTPases. We found that
expression of RalA-28N in H-Ras12V-transformed HEK–
HT cells (Fig. 6A) did curb the ability of Ras-transformed
cells to grow in soft agar (Fig. 6D) without decreasing
Akt or ERK phosphorylation (Fig. 6B). Similarly, there
was a growth reduction in Ras12V37G-expressing cells
infected with the RalA-28N-expressing retrovirus (Fig.
6D). Thus, RalGEFs are necessary for Ras-mediated
transformation.
Whereas RalA-28N attenuated Ras-induced transfor-
mation, it did not completely block it. Such a result
could suggest the presence of other effectors downstream
of Ras12V37G that could contribute to the oncogenic
signal. Therefore, to directly test whether activation of
RalGEFs alone is sufficient for transformation, we evalu-
ated whether a constitutively activated RalGEF could
cause the transformation of HEK–HT cells. As described
above, there are four known RalGEF proteins that can
interact with Ras (Wolthuis and Bos 1999; de Bruyn et al.
2000; Rebhun et al. 2000; Shao and Andres 2000), with
the Ras-binding domain of Rlf having the highest affinity
for GTP–Ras (Esser et al. 1998). Therefore, we estab-
lished HEK–HT cells stably expressing Rlf-CAAX, a
plasma membrane-targeted and constitutively activated
version of Rlf (Wolthuis et al. 1997; Ramocki et al. 1998).
We verified expression of this protein by immunoblot
analysis (Fig. 6A), and, importantly, confirmed that Rlf-
CAAX did not activate either ERK or Akt (Fig. 6B) but
did activate Ral, as assessed by an increase in Ral–GTP
Figure 5. The MAP-kinase and PI3-kinase pathways together are not transforming, but greatly enhance Ras12V37G-mediated trans-
formation. (A) Coexpression of Ras12V effector mutants was confirmed from direct sequencing of H-Ras cDNA to identify the point
mutations giving rise to 40C (green), 37G (blue), or 35S (red) effector mutations or the corresponding nucleotide of endogenous H-Ras
(black in vector control) in the described double-infected HEK–HT cells. (B) Anchorage-independent growth of HEK–HT cells express-
ing the described combinations of Ras12V mutants with control vector (black bars) or the described effector mutants, Raf1-22W or
p110-CAAX (white bars), as calculated from the average number of colonies observed from three plates, and expressed as the percent
of colonies observed in Ras12V+vector-transformed cells. A total of 50,000 Ras12V+vector-transformed HEK–HT yielded 295 ± 83
colonies in soft agar. (C) Anchorage-independent growth of HEK–HT cells expressing Ras12V and control vector, vector alone, or
Raf1-22W and p110-CAAX, as calculated from the average number of colonies observed from three plates, and expressed as the
percent of colonies observed in Ras12V+vector-transformed cells. A total of 50,000 Ras12V+vector-transformed HEK–HT yielded 463
± 55 colonies in soft agar.
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levels (Fig. 6C). The cells were next tested for anchorage-
independent growth. Expression of Rlf-CAAX was suffi-
cient to support the anchorage-independent growth of
HEK–HT cells up to 60% of the level seen in the same
cells transformed by Ras12V37G (Fig. 6D). Although it
remains formally possible that this Rlf-CAAX-mediated
transformation is unique to HEK cells, the observation
that H-Ras12V37G transformed T-Ag and hTERT-ex-
pressing HEK cells, astrocytes and fibroblasts suggest
that activation of a single RalGEF may be transforming
in other human cell types. When taken together with the
ability of the Ral dominant-negative to impair Ras12V
transformation, these results suggest that oncogenic
transformation of human cells by Ras12V37G is medi-
ated, at least in part, by the activation of RalGEFs.
Ras12V37G is essential for Ras-induced tumorigenesis
of human cells
Ras12V37G expression alone is sufficient to promote an-
chorage-independent growth of HEK cells. We next
sought to determine whether signaling by this protein is
required for the prior observations that primary human
cells expressing hTERT and T-Ag require oncogenic Ras
to form tumors when injected in immuno-compromised
mice (Hahn et al. 1999). HEK–HT cells expressing
H-Ras12V35S and H-Ras12V40C (Fig. 5A) were stably
infected with either an empty vector control or an
H-Ras12V37G-expressing construct. The resultant cells
were then each injected into four immuno-compromised
mice to assay for tumor growth. HEK–HT cells that co-
ordinately expressed all three effector mutants readily
formed tumors (Fig. 7) at a rate indistinguishable from
that caused by oncogenic H-Ras12V (data not shown;
Hahn et al. 1999). However, cells lacking Ras12V37G
expression completely failed to form detectable masses
in vivo, even after ∼50 days, that is, twice as long as
Ras12V37G-expressing cells required to form tumors
(Fig. 7). Effectors of Ras12V37G are therefore necessary
for Ras-dependent tumorigenesis in vivo. We next ad-
dressed whether Ras12V37G alone is sufficient for tu-
morigenic growth. In this case, HEK–HT cells expressing
Ras12V37G failed to form tumors in vivo (data not
shown). Such a result is consistent with our observations
that Ras12V37G is not as potent as Ras12V at promoting
anchorage-independent growth (Fig. 1), and the known
roles of the PI3-kinase and MAP-kinase pathways
(Shields et al. 2000) in the more complex process of tu-
Figure 6. RalGEFs are essential for Ras transfor-
mation of human cells. (A) RalA-28N and Rlf-
CAAX expression was confirmed in HEK–HT or
Ras12V-transformed HEK–HT cells, respectively,
by immunoblotting with either an anti-Ral anti-
body (top) or an anti-HA antibody specific for the
HA epitope cloned into Rlf (bottom). Actin levels
serve as loading controls. (B) Phosphorylated Akt
(P-AKT) or ERK 1 and 2 (P-ERK 1/2) levels were
determined in the described cells by immunoblot-
ting with antibodies specific for the phosphory-
lated forms of these proteins. The total amount of
Akt, ERK 1/2 or actin detected by anti-Akt, ERK,
or actin antibodies serve as loading controls. (C)
Ral–GTP levels were determined in the described
cells by binding cellular Ral–GTP to the recombi-
nant Ral-binding domain of the RalBP protein, fol-
lowed by immunoblotting with a RalA-specific
antibody. The total amount of Ral detected by the
same anti-RalA antibody serve as loading controls.
(D) Anchorage-independent growth of Ras12V or
Ras12V37G-transformed HEK–HT cells in the ab-
sence (vector) or presence of RalA28N, or HEK–
HT cells in the absence (vector) or presence of Rlf-
CAAX, as calculated from the average number of
colonies observed from three plates, and expressed
as the percent of colonies observed in Ras12V
(black bars) or Ras12V37G (white bars) trans-
formed cells. A total of 50,000 Ras12V-trans-
formed HEK–HT cells yielded 295 ± 83 colonies in
soft agar.
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morigenesis (Stanbridge and Wilkinson 1980). Thus,
whereas effectors of H-Ras12V37G are not alone suffi-
cient for tumorigenic growth they are, unlike in murine
cells, essential for this process.
Discussion
Studies done primarily in NIH 3T3 and other rodent fi-
broblast model cell systems have established that the
transforming activity of Ras is mediated largely by acti-
vating the Raf>Mek>Erk signal cascade. In NIH 3T3
cells, activated mutants of Raf-1 (Bonner et al. 1985;
Stanton et al. 1989; Leevers et al. 1994; Stokoe et al.
1994) or its target MEK (Alessi et al. 1994; Mansour et al.
1994) are completely sufficient to replace oncogenic Ras
in the tumorigenic assays. This prompted earlier sugges-
tions that Raf is the key effector of Ras transformation.
Although studies of Ras transformation using other cell
types now indicate that Raf-independent effector func-
tion also contributes to Ras transformation (Shields et al.
2000), Raf is still generally considered to form the back-
bone of Ras oncogenesis. The importance of this path-
way in Ras transformation is reflected by the current
evaluation of anti-Raf and anti-MEK strategies in pre-
clinical and clinical studies (Monia et al. 1996; Sebolt-
Leopold et al. 1999; Stevenson et al. 1999; Cunningham
et al. 2000; Kloog and Cox 2000; Sebolt-Leopold 2000;
Stein and Waterfield 2000). There is also strong evidence
for an important supportive role for PI3-kinase in Ras
transformation (Rodriguez-Viciana et al. 1997; Tol-
kacheva and Chan 2000). Aside from limited evidence
for the importance of RalGEFs in Ras transformation,
the role of other effectors in Ras transformation remains
largely unresolved. In the present study, we determined
unexpectedly that activation of the Raf and PI3-kinase
effector pathways, either alone or together, was not suf-
ficient to cause transformation of human cells. Instead,
we found that activation of the RalGEF effector signaling
alone, although found previously to not be sufficient to
transform rodent fibroblasts, was sufficient to cause
growth transformation of a variety of human cells. More-
over, because expression of an activated RalGEF did not
lead to an increase in ERK or Akt phosphorylation, we
rule out indirect activation of the MAP-kinase and PI3-
kinase pathways by RalGEFs as a mechanism accounting
for the transforming capacity of RalGEFs. Whereas we
did find that Raf and PI3-kinase could cooperate with
H-Ras12V37G to promote transformation, our results
suggest that it is the activation of effectors of this Ras
mutant, such as RalGEFs, that is critical for Ras trans-
formation in human cells, at least in this model system.
As such, we propose an effector-usage model, whereby
multiple effectors of Ras contribute to the oncogenic sig-
nal, but that there exists significant differences between
humans and mice in the relative potency of each path-
way. Such species-specific differences in carcinogenesis
are not restricted to Ras-related neoplasms. Transgenic
mice lacking functional alleles of the tumor suppressors
p53 (Donehower et al. 1992), Rb (Jacks et al. 1992), and
NF-1 (Jacks et al. 1994), to name a few, also fail to give
rise to the same types of tumors observed in familial
human diseases harboring the same genetic changes
(Cavenee et al. 1985; Legius et al. 1993; Colman et al.
1995; Kleihues et al. 1997). The recurrent discrepancies
in the tumor phenotypes between humans and mice em-
phasize the value of dissecting oncogenesis in human
cells.
We have shown that RalGEFs are transforming, sup-
porting the premise that these proteins mediate, at least
in part, Ras12V37G transformation. An interesting par-
allel to these findings is the observation that RalGEFs,
and not other Ras effectors, are critical for proliferation
of PC12 cells, although, in this case, RalGEFs oppose
the growth-inhibitory action of Raf and PI3-kinase (Goi
et al. 1999). With regards to the potency of RalGEFs for
transformation, we note that whereas RalA-28N inhib-
ited Ras-mediated transformation, it did not abolish it.
Similarly, Rlf-CAAX promoted anchorage-independent
growth, but not to the same level as Ras12V37G. It
therefore remains possible that Ras12V37Gmay activate
other effectors, in addition to RalGEFs, to promote the
transformed phenotype. For example, H-Ras12V37G has
been shown recently to retain the ability to bind and
activate phospholipase C  and stimulate production of
two second messengers, inositol trisphosphate and diac-
ylglycerol (Cullen 2001). These second messengers in
turn promote an increase in intracellular calcium and
activation of protein kinase C, events that may contrib-
ute to growth transformation. Alternatively, the mu-
tants utilized to implicate a RalGEF pathway may be
only partially effective in mimicking the consequences
of Ras activation of RalGEFs. For example, at least four
distinct RalGEFs have been identified as Ras effectors,
and, hence, expression of only one activated form may
Figure 7 Ras12V37G is essential for tumor growth. Tumor vol-
ume (mm3) of four mice injected with HEK–HT cells expressing
H-Ras12V40C and H-Ras12V35S either in the absence (vector:
) or presence () of H-Ras12V37G, plotted against
time (days).
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not be sufficient. Consistent with this possibility, we
found that coexpression of two constitutively activated
RalGEF members caused a more robust transformation
than one alone (data not shown).
The observation that Ras12V37G was required for tu-
morigenic growth supports the notion that RalGEFs are
important for tumorigenesis. Because RalGEFs are bona
fide effectors of Ras (Wolthuis and Bos 1999), and Ras is
commonly activated in human cancers, either through
an activating mutation (Bos 1989) or by inappropriate
activation of growth factor receptors (Shields et al. 2000),
it stands to reason that the RalGEF pathway is activated
in at least some human cancers. We also point out that a
RalGEF has been identified that is oncogenic (D’Adamo
et al. 1997), opening up the possibility that this pathway
could even be activated selectively during tumorigen-
esis. We can, however, only speculate on the mechanism
whereby RalGEFs transform human cells. The only
known substrates for these proteins are the monomeric
G-proteins RalA and RalB. RalGEFs bind to the GDP-
bound state of Ral and facilitate the exchange of GDP for
GTP, thereby activating these proteins (Wolthuis and
Bos 1999; de Bruyn et al. 2000; Rebhun et al. 2000; Shao
and Andres 2000). However, no oncogenic potential has
been shown for activated Ral proteins alone, although
activated Ral can modestly potentiate the transforming
activity of activated Raf in rodent fibroblast transforma-
tion assays (Urano et al. 1996; White et al. 1996). Con-
sistent with these data, an activated form of Ral failed to
promote significant growth of the human cells in soft
agar (data not shown). Thus, it is possible that activation
mutations in Ral may not recapitulate the activation by
Rlf-CAAX or H-Ras. Alternatively, Rlf-CAAX may acti-
vate other signaling proteins, either because they are
natural substrates or by virtue of Rlf-CAAX overexpres-
sion or constitutive membrane targeting. Future studies
will be needed to determine how RalGEFs transform hu-
man cells and whether RalGEFs are up-regulated in hu-
man tumors that harbor mutated Ras.
In murine cells, the MAP-kinase pathway is clearly
critical for tumorigenesis and is also commonly acti-
vated in human tumors (Hoshino et al. 1999). Conse-
quently, this pathway has been the target of aggressive
efforts to develop inhibitors to treat human cancers. A
variety of pharmacologic and antisense approaches have
been developed to block the activities of Raf and MEK
and are now under clinical evaluation (Stevenson et al.
1999; Cunningham et al. 2000; Kloog and Cox 2000; Se-
bolt-Leopold 2000). Similarly, PI3-kinase has been impli-
cated in human cancer, particularly for its role in cell
survival and proliferation. In certain cancer types, the
PI3-kinase gene is amplified, the protein overexpressed
(Phillips et al. 1998; Ma et al. 2000) or expression of the
PTEN gene, a negative regulator of the PI3-kinase path-
way, is lost (Cantley and Neel 1999). Targeted inhibition
of specific PI3-kinases has also been proposed as an av-
enue of cancer treatment (Stein and Waterfield 2000).
Given that inhibition of these Ras effectors has profound
effects on tumor growth and that Ras12V37G was found
to be essential for transformation of human cells, we
speculate that inhibition of effectors of Ras12V37G,
such as RalGEFs, may also hold promise as a cancer
treatment strategy.
In summary, there is considerable debate regarding the
accuracy of mouse models for human cancer. In this
study of both human and murine cells, we now show
that the signaling pathway engaged by H-Ras12V37G
is sufficient for Ras-dependant transformation and nec-
essary for tumor formation in human cells, and that
RalGEFs, known targets of this effector mutant, are criti-
cal components of this process. A surprising observation
from our analyses was that the two most critical effec-
tors of Ras transformation of rodent fibroblasts were not
sufficient, either alone, or in combination to cause trans-
formation of the human cells. These observations high-
light the value of dissecting the signaling pathways of
oncoproteins in human cells and suggest that the effec-
tors of H-Ras12V37G, such as RalGEF, could represent
potential targets for the development of anti-Ras drugs
for the treatment of human cancers.
Materials and methods
Cell lines
Retrovirus constructs were created by subcloning FLAG–H-Ras
and FLAG–H-Ras12V (an amino-terminal FLAG tag was in-
serted in frame into H-Ras or H-Ras12V by PCR) in the absence
or presence of effector domain mutants S35, C40 or G37 (White
et al. 1995; Rodriguez-Viciana et al. 1997) generated by site-
directed mutagenesis, RalA-28N [the 28N mutation (Urano et
al. 1996) was introduced by site-directed mutagenesis into RalA
(Frech et al. 1990), a kind gift of R.A. Weinberg (Massachusetts
Institute of Technology, Cambridge, MA)], HA-Rlf-CAAX
(Wolthuis et al. 1997), p110-CAAX (Rodriguez-Viciana et al.
1997), Raf1-22W (Stanton et al. 1989), and T-Ag [generated by
PCR amplifying the early region of SV40 of plasmid pSVneo
(Southern and Berg 1982) with primers that incorporate BamHI
and EcoRI sites] into pBabe vectors (Morgenstern and Land
1990) creating the following plasmids pBabepuro: FLAG–H-
Ras, FLAG–H-Ras12V (and 35S, 37G, or 40C), HA-Rlf-CAAX,
p110-CAAX, and Raf1-22W; pBabebleo: FLAG–H-Ras12V
(and 35S or C40), RalA-28N; and pBabeneo: T/t-Ag. FLAG–H-
Ras12V35S was also cloned into the vector pWZL-Blast [a kind
gift of J.P. Morgenstern (Millennium Pharmaceuticals Inc., Cam-
bridge, MA)].
At the earliest passage, the appropriate derived amphotrophic
retroviruses encoding H-Ras or effector mutants thereof or Ras
effectors were used to infect T-Ag + hTERT expressing primary
HEK (Armbruster et al. 2001), human astrocyte (Rich et al.
2001), human BJ fibroblasts (Hahn et al. 1999), or primary mu-
rine fibroblasts from two independent strains of C57/Bl6;129Sv
mice stably infected with pBabeneoT/t-Ag [a kind gift of X.-F.
Wang and A.M. Pendergast (Duke University Medical Center,
Durham, NC)] or NIH 3T3 (Khosravi-Far et al. 1996) cells, simi-
lar to approaches described previously (Hahn et al. 1999; Rich et
al. 2001). Stable polyclonal populations resistant to the appro-
priate drug selection markers were assayed for anchorage-inde-
pendent growth by the third confluent plate. The same proce-
dure was followed to add additional transgenes.
Immunoblotting
Exponentially growing cells from the described cell lines were
lysed, protein concentrations were measured by Lowry assay
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(Bio-Rad), and 30 µg of soluble lysate separated by SDS-PAGE
and immunoblotted similar to methods described previously
(Armbruster et al. 2001) by use of the M2 anti-FLAG (Sigma),
anti-RalA (Signal Transduction Laboratories), E-10 anti-Raf1,
C-2 or I-19 anti-actin (Santa Cruz Biotechnology), or 12CA5
anti-HA (Roche) antibodies to detect FLAG–H-Ras, RalA28N,
Raf1-22W, actin, and HA-Rlf-CAAX. To monitor activation of
the MAP-kinase and PI3-kinase pathways, the described cell
lines were serum starved in medium supplemented with 0.5%
fetal bovine serum for 48 h, lysed, resolved by SDS-PAGE, and
immunoblotted similar to that described above. The K-23 anti-
ERK1/2 (Santa Cruz), E10 anti-phospho(Thr 202/Tyr 204)-p42/
44 MAPK, anti-Akt (Cell Signaling Technology), and S472 anti-
phospho(Ser 473)-Akt (New England Biolabs) antibodies were
used to detect ERK 1 and ERK 2, phosphorylated ERK 1 and ERK
2, Akt, and phosphorylated Akt, respectively.
Ral–GTP assay
Levels of endogenous Ral–GTP were assayed as described pre-
viously (Murphy et al. 2002) by incubating cell lysates with
glutathione-agarose bound recombinant GST–RalDB (produced
and purified from bacteria), which adheres specifically to Ral in
the GTP-bound state. Beads were washed and bound proteins
resolved by SDS-PAGE and Ral detected by immunoblotting
with the aforementioned anti-RalA antibody. Total Ral levels
were determined by immunoblotting lysates with the same an-
tibody.
RT–PCR
Total RNA was isolated and RT–PCR amplified using method-
ologies described previously (Hahn et al. 1999; Rich et al. 2001)
with primers specific for H-Ras (5-ACGACGATGACAAGA
CGGAA-3 and 5-ATGGCGCTGTACTCCTCCT-3), p110 (5-
GACAATGTGAACACTCAAAGAG-3; and 5-CACCAATAG
GGTTCAG CAGA-3) and GAPDH (Hahn et al. 1999). To iden-
tify specific effector mutants, H-Ras RT–PCR amplified prod-
ucts were sequenced to determine the nucleotide at positions
+105, +111, and +121 (corresponding to the 35S, G37, and 40C
mutations, respectively).
Soft agar
Cells were suspended in soft agar and colonies >30 cells scored
after 3 wk, as described previously (Cifone and Fidler 1980).
Assays were done in triplicate, and inmost cases independently,
at least twice.
Tumors
Under a protocol approved by the Duke University Institutional
Animal Care and Use Committee, 2 × 106 cells were injected
subcutaneously into the flanks of four SCID/Beige mice, after
which tumor volumes were determined at regular intervals, as
described previously (Hahn et al. 1999; Gou et al. 2001).
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